Translate this page into:
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER: Review Article
doi:
10.4103/2278-330X.155699
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
1
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 ONN
*Corresponding author: Dr. Syed Imran Ali Shah. s.shah10@imperial.ac.uk
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in "castration syndrome", a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen.
Keywords
References
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
- Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014;11:197-212.
- Connolly RM, Carducci MA, Antonarakis ES. Use of androgen deprivation therapy in prostate cancer: Indications and prevalence. Asian J Androl 2012;14:177-86.
- Thomas BC, Neal DE. Androgen deprivation treatment in prostate cancer. BMJ 2013;346:e8555.
- Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology 1986;27:21-8.
- Allan CA, Collins VR, Frydenberg M, McLachlan RI, Matthiesson KL. Androgen deprivation therapy complications. Endocr Relat Cancer 2014;21:T119-29.
- Casey RG, Corcoran NM, Goldenberg SL. Quality of life issues in men undergoing androgen deprivation therapy: A review. Asian J Androl 2012;14:226-31.
- Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group′s studies of cancer of the prostate. Cancer 1973;32:1126-30.
- Orlando M, Chacón M, Salum G, Chacón DR. Low-dose continuous oral fosfestrol is highly active in ′hormone-refractory′ prostate cancer. Ann Oncol 2000;11:177-81.
- von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. Estrogen therapy and liver function - Metabolic effects of oral and parenteral administration. Prostate 1989;14:389-95.
- Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42:220-9.
- Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer - Forward to the past? J Urol 2003;169:1735-7.
- Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: The randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol 2013;14:306-16.
- Lycette JL, Bland LB, Garzotto M, Beer TM. Parenteral estrogens for prostate cancer: Can a new route of administration overcome old toxicities? Clin Genitourin Cancer 2006;5:198-205.
- Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update 2007;13:175-87.
- Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol 2010;224:305-10.
- Bracamonte MP, Miller VM. Vascular effects of estrogens: Arterial protection versus venous thrombotic risk. Trends Endocrinol Metab 2001;12:204-9.
- Sherwin BB. Estrogen and cognitive functioning in women: Lessons we have learned. Behav Neurosci 2012;126:123-7.
- Dören M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: A meta-analysis. Hum Reprod 2003;18:1737-46.
- Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004;172:2203-7.